Verition Fund Management
CLDX icon

Verition Fund Management’s Celldex Therapeutics CLDX Stock Holding History

Verition Fund Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-55,140
Closed -$1.43M – 3566
2025
Q3 		$1.43M Buy
55,140
+21,269
+63% +$493K 0.01% 2257
2025
Q2 		$689K Buy
33,871
+15,475
+84% +$301K ﹤0.01% 2734
2025
Q1 		$334K Buy
+18,396
New +$411K ﹤0.01% 2812
2022
Q2 		– Sell
-87,230
Closed -$2.97M – 2435
2022
Q1 		$2.97M Buy
87,230
+33,368
+62% +$1.07M 0.04% 697
2021
Q4 		$2.08M Buy
+53,862
New +$2.35M 0.02% 859
2021
Q2 		– Sell
-133,064
Closed -$2.74M – 1912
2021
Q1 		$2.74M Sell
133,064
-42,475
-24% -$975K 0.03% 339
2020
Q4 		$3.08M Buy
175,539
+7,915
+5% +$142K 0.03% 286
2020
Q3 		$2.49M Buy
+167,624
New +$1.96M 0.05% 212

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Verition Fund Management's CLDX Position: Q4 2025 in Review

Verition Fund Management sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 55,140 shares — an estimated $1.43M sold.

Verition Fund Management first reported a position in CLDX in Q3 2020 and held it in 8 quarters. The position peaked at $3.08M in Q4 2020. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • Verition Fund Management reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 55,140 Celldex Therapeutics shares in Q4 2025, an estimated $1.43M.
  • Verition Fund Management first reported a position in Celldex Therapeutics in Q3 2020 and held it in 8 quarters.
  • Verition Fund Management's Celldex Therapeutics position peaked at $3.08M in Q4 2020.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.